CN105816705A - Corn stigma and phosphatidylserine-containing drug and preparation method thereof - Google Patents
Corn stigma and phosphatidylserine-containing drug and preparation method thereof Download PDFInfo
- Publication number
- CN105816705A CN105816705A CN201610214198.2A CN201610214198A CN105816705A CN 105816705 A CN105816705 A CN 105816705A CN 201610214198 A CN201610214198 A CN 201610214198A CN 105816705 A CN105816705 A CN 105816705A
- Authority
- CN
- China
- Prior art keywords
- phosphatidylserine
- stigma maydis
- corn stigma
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 84
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 240000008042 Zea mays Species 0.000 title abstract description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 title abstract 9
- 235000005822 corn Nutrition 0.000 title abstract 9
- 239000000284 extract Substances 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 15
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 241001122767 Theaceae Species 0.000 claims 1
- 230000015654 memory Effects 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 244000269722 Thea sinensis Species 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000008098 Oxalis acetosella Nutrition 0.000 description 2
- 241001119526 Paullinia Species 0.000 description 2
- 235000010240 Paullinia pinnata Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- -1 ester compound Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical class OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a corn stigma and phosphatidylserine-containing drug and a preparation method thereof. The corn stigma and phosphatidylserine-containing drug comprises the following raw materials in parts by weight: 1-100 parts of corn stigma and 0.001-0.4 part of phosphatidylserine. The preparation method comprises the following steps: carrying out drying, reflux extraction, concentration, primary filtration and fine filtration on the corn stigma serving as raw materials to obtain a corn stigma extract, adding the phosphatidylserine in the corn stigma extract and making into drink, tea or dosage forms such as tablets, granules, capsules and the like. The drug disclosed by the invention has the advantages that the phosphatidylserine is added in the conventional corn stigma, the original efficacies of relieving summer heat and clearing heat, alleviating swelling and inducing diuresis, reducing blood fat, blood pressure and blood glucose and the like of the corn stigma are retained and the efficacies of improving memory, preventing senile dementia and the like are enhanced due to the addition of the phosphatidylserine, so that the drug is suitable for old people, and is a popular food for people of all ages due to the addition of the phosphatidylserine.
Description
Technical field
The present invention relates to technical field of medicament, a kind of medicine comprising Stigma Maydis and Phosphatidylserine and preparation method thereof.
Background technology
Stigma Maydis is also referred to as maize palpus.The most medicinal record sees " the southern regions of the Yunnan Province book on Chinese herbal medicine " in 1476, is the traditional Chinese crude drug of China, and Stigma Maydis is the zeistic style of grass and stigma.There are inducing diuresis to remove edema, effect of liver heat removing function of gallbladder promoting.Tall and big annual cultivated plant.Stalk is sturdy, uprightly, high 1～4m, the most not branch, often there is aerial root at base portion joint.Before 2012, Stigma Maydis excludes integration of edible and medicinal herbs catalogue, is not the most approved as new resource food, and within 2010, version pharmacopeia is not the most included, and therefore Stigma Maydis is not used for the foundation of bread and cheese.On October 18th, 2012, it is as follows that Ministry of Public Health supervision letter [2012] 306 discloses " Ministry of Public Health is about the reply of Stigma Maydis relevant issues " content: after deliberation, a reply is hereby given as follows: Stigma Maydis has certain edible history in China, does not finds safety problem, can manage as bread and cheese.This bulletin is that the exploitation of Stigma Maydis product lays a good foundation.
Phospholipid is as a kind of bioactive substance; there are physicochemical property and the nutritive value of uniqueness; food, health product, medicine and feedstuff industry worldwide are widely used, and people can play regulation blood fat by using phospholipid, improve the effect of the physiological functions such as memory, the liver protecting, nourishing the brain and improving intelligence and slow down aging.Phosphatidylserine is a member in phospholipid family, Phosphatidylserine, also known as composite nerve acid, it is called for short PS, extracted by crude soya bean oil expression residue, it it is the active substance of cell membrane, it is particularly present in brain cell, its function mainly improves neurocyte function, the conduction of regulation Nerve impulse, promote brain memory function, owing to it has the strongest lipotropy, blood brain barrier can be run through after absorption and enter brain, play vascular smooth muscle cell of releiving, increase the effect of brain blood supply, it is uniquely can the phospholipid of regulating cell film key protein functional status, it it is the indispensable material of human body.As long as so the meals agent normally taking Phosphatidylserine class can't bring extra burden to health, and having passed through Bureau of Drugs Supervision's certification of many countries.
Phosphatidylserine is described as " the intelligent nutrition element " that after choline and " NAOHUANGJIN " DHA is the most emerging.Expert thinks, this natural materials can help cell wall to keep pliability, and can strengthen the efficiency of neurotransmitter transmitting brain signal, helps brain high-efficiency operation, excites the state of activation of brain.Specifically, Phosphatidylserine has a following functions:
1. improve cerebral function, focus on, improve memory；America and Europe emerges a large amount of meta-analysis (meta-analysis refers to that the multiple independent studies results being done certain problem carry out the most comprehensive of system) to Phosphatidylserine, and its main purpose is by the concentrated expression the most objectively of conventional result of study out.Analyzing 9 double blindings, placebo, the clinical trial of totally 1224 example patients participations, result shows, after supplementing Phosphatidylserine, significantly improves about cognitive and memory parameter.Certainly, supplementary Phosphatidylserine can improve longterm memory, the most cognitive and free talk and logicality speech ability；With advancing age, in Phosphatidylserine and other important brains, chemical substance can gradually decrease, thus causes memory, cognitive power to weaken.Supplementary Phosphatidylserine can increase brain bur number, the mobility of brain cell membrane and promote glucose metabolism in brain cell, so that brain cell is more active, promotes that attention is concentrated, stepping up vigilance property and memory.Italy, the Scandinavian Peninsula and Europe other countries the most extensively apply Phosphatidylserine supplement to treat the cognitive disorder disease of old and feeble initiation and old memory loss.
2. improving student performance, special test Phosphatidylserine alleviates the effect of stress, and test have employed double blinding, placebo, continuous 30 days, gives every day Health College Students 300 milligrams of Phosphatidylserine.University students must complete have the mathematics test acquired a certain degree of difficulty within preset time, and records them in the face of the reaction of pressure.It was found that use the student of Phosphatidylserine to be all better than matched group in terms of reagency, confidence and performance, their achievement in examination is more preferable.Studying the research for SiChuan middle school, 120 Chongqing Senior student for one also to find, taking the student of strengthening Phosphatidylserine, after 40 days, the memory of its language and non-language is all significantly increased.
3. alleviate pressure, promote the recovery of brain fag, balance emotion；Multiple studies have shown that the level of stress hormone too much in Phosphatidylserine can significantly reduce work strain person's body eases off the pressure, and alleviates brain tired；Phosphatidylserine may also act to affect in brain the neurotransmitter levels of mood, attention can be promoted to concentrate, stepping up vigilance property and memory, help improper release emotion (as depressed, dejected etc.).
4. help to repair cerebral lesion；Phosphatidylserine is one of main component of brain neuroblastoma, can the activity of various enzymes in nutrition and activation brain, the minimizing process of neurotransmitter can be delayed, contribute to repairing, updating brain damage cell and remove harmful substance.It can make the memory of old people return to 14 years front levels, and research display, edible phospholipid acyl serine is after 12 weeks, and the people of 66 years old has 52 years old man memory power；In addition, Phosphatidylserine and DHA can mutually promote absorption, play a protective role neural 2A cell.Abundant Phosphatidylserine can increase the mobility of cell membrane, promotes the growth of intelligence.Phosphatidylserine can protect central nervous system together with DHA, promotes that fetal intelligence is grown；Why Phosphatidylserine can strengthen the intelligence of people, main reason is that it can quickly pass through blood brain barrier, enters brain.Play, at brain, cerebral capillary smooth muscle cell of releiving, increase the effect of brain blood supply.So had in recent years a lot of for the product in terms of apoplexy all using PS as raw material.
Phosphatidylserine is a kind of composition being naturally occurring in food, there is also in breast milk.Meat and Fish all contain the content in Phosphatidylserine, brain or internal organs (such as liver, kidney) higher.In milk product and vegetable, (except beans), the content of Phosphatidylserine is considerably less.The change of modern's dietary habit (such as no longer edible offals); the consciousness of edible health food strengthens (such as eat low fat, low cholesterol food and avoid edible a large amount of meat products), and food crisis (such as bovine spongiform encephalopathy and foot and mouth disease) to cause people to take in the quantity of Phosphatidylserine the most fewer and feweri.More seriously, the natural phospholipid content in lipid that modern industrialization is produced and oils product declines, and further reduces normal person and should absorb the quantity of Phosphatidylserine every day.In general, if having more meat and Fish in diet, the intake of Phosphatidylserine is about 180 mg/day；If fat content is low in food, then every day, the intake of Phosphatidylserine will only be 100 milligrams, even less than 50 milligrams.According to statistics, between the intake of normal person's Phosphatidylserine every day and normal demand amount, gap is between 70 150 milligrams, and vegetarian particularly lacks, and its gap reaches 200 250 milligrams.For these reasons, normal person's daily requirement supplements the pure Phosphatidylserine of 100 300 milligrams, and for vegetarian, low fat or low-cholesterol diet person and old people, this point is more important.Additionally, some other dietary habit also can reduce the content of Phosphatidylserine in brain.Such as, diet lacks omega 3 fatty acid the content of Phosphatidylserine in brain can be made to reduce by 28%, and then change the biochemical function of cerebral hippocampus body.
Summary of the invention
It is an object of the invention to provide medicine comprising Stigma Maydis and Phosphatidylserine of a kind of heat clearing away of can relieving summer heat, memory reinforcing and preparation method thereof, with the problem solving to propose in above-mentioned background technology.
For achieving the above object, the present invention provides following technical scheme:
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 1-100 part, Phosphatidylserine 0.001-0.4 part.
As the further scheme of the present invention: described in comprise the medicine of Stigma Maydis and Phosphatidylserine, include according to the raw material of weight portion: Stigma Maydis 5 parts, Phosphatidylserine 0.1 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 60-70 DEG C, adds the water of 3-15 times, temperature controls at 80-110 DEG C, refluxes and extracts 0.5-4h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 70-90 ° of C, carry out evacuation being compressed to relative density is 1.0-1.1；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain pharmaceutical preparation.
As the present invention further scheme: described pharmaceutical preparation is beverage, tea, tablet, granule or capsule.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention adds Phosphatidylserine in traditional Stigma Maydis, not only retain former Stigma Maydis to relieve summer heat heat clearing away, swelling diuretic, the effects such as blood fat reducing, blood pressure, blood glucose, separately because adding Phosphatidylserine, can be with effects such as memory reinforcing, prevention senile dementias, it is applicable not only to old people's use, also becomes all-ages popular food because adding Phosphatidylserine.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the technical scheme of this patent is described in more detail.
Embodiment 1
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 1 part, Phosphatidylserine 0.001 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 60 DEG C, adds the water of 3 times, temperature controls at 80 DEG C, refluxes and extracts 0.5h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 70 ° of C, carry out evacuation being compressed to relative density is 1.0；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain beverage.
Embodiment 2
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 5 parts, Phosphatidylserine 0.1 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 62 DEG C, adds the water of 6 times, temperature controls at 87 DEG C, refluxes and extracts 1.3h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 75 ° of C, carry out evacuation being compressed to relative density is 1.02；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain tea.
Embodiment 3
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 50 parts, Phosphatidylserine 0.2 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 65 DEG C, adds the water of 9 times, temperature controls at 95 DEG C, refluxes and extracts 2.1h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 80 ° of C, carry out evacuation being compressed to relative density is 1.05；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain tablet.
Embodiment 4
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 80 parts, Phosphatidylserine 0.3 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 68 DEG C, adds the water of 12 times, temperature controls at 102 DEG C, refluxes and extracts 3h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 85 ° of C, carry out evacuation being compressed to relative density is 1.08；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain granule.
Embodiment 5
A kind of medicine comprising Stigma Maydis and Phosphatidylserine, includes according to the raw material of weight portion: Stigma Maydis 100 parts, Phosphatidylserine 0.4 part.
The preparation method of the described medicine comprising Stigma Maydis and Phosphatidylserine, specifically comprises the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 70 DEG C, adds the water of 15 times, temperature controls at 110 DEG C, refluxes and extracts 4h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 90 ° of C, carry out evacuation being compressed to relative density is 1.1；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain capsule.
Pharmacological action
Fatty oily 2.5%, the volatile oil 0.12% of Stigma Maydis, sets gelatinoid 3.8%, resin 2.7%, bitterness glucoside 1.15%, Saponin 3.18%, alkaloid 0.05%.Also containing cryptoxanthine, vitamin C, pantothenic acid, inositol, vitamin K, sitosterol, stigmasterol, malic acid, citric acid, tartaric acid, oxalic acid etc..Additionally, also containing a large amount of potassium nitrate, a-gives birth to quinone.At present, separate from Stigma Maydis and the compound of qualification mainly has flavone and glycoside, sterol, alkaloid, saccharide, organic acid, volatile oil, trace element and multivitamin etc..Stigma Maydis sweet in the mouth, property puts down, has calming liver and clearing heat, effect of diuresis damp eliminating, and normal drink is not only relieved summer heat heat clearing away, swelling diuretic, it is also possible to the effects such as blood fat reducing, blood pressure, blood glucose.
Phosphatidylserine is usually located at the internal layer of cell membrane, and the phosphoglycerol esters in phosphoric ester compound, is one of cell membrane component, relevant with a series of film function.Especially at the nervous system of human body, it is cell membrane important of brain, one of constituent, the various functions (especially to the memory of brain and stablizing of emotion) of brain are played important regulation effect simultaneously, as it can affect the mobility of cell membrane, permeability, and metabolism and the synthesis of multiple enzyme can be activated；Phosphatidylserine can be utilized serine synthetically produced by human body, and it is the transmission of chemical message in can affecting brain, and helps brain cell to store and reading data, is to maintain brain normal memory power, reaction and the important nutrient of healthy emotion.
The present invention adds Phosphatidylserine in traditional Stigma Maydis, not only retain former Stigma Maydis to relieve summer heat heat clearing away, swelling diuretic, the effects such as blood fat reducing, blood pressure, blood glucose, separately because adding Phosphatidylserine, can be with effects such as memory reinforcing, prevention senile dementias, it is applicable not only to old people's use, also becomes all-ages popular food because adding Phosphatidylserine.
Above the better embodiment of this patent is explained in detail, but this patent is not limited to above-mentioned embodiment, in the ken that one skilled in the relevant art is possessed, it is also possible to various changes can be made on the premise of without departing from this patent objective.
Claims (4)
1. the medicine comprising Stigma Maydis and Phosphatidylserine, it is characterised in that include according to the raw material of weight portion: Stigma Maydis 1-100 part, Phosphatidylserine 0.001-0.4 part.
The medicine comprising Stigma Maydis and Phosphatidylserine the most according to claim 1, it is characterised in that include according to the raw material of weight portion: Stigma Maydis 5 parts, Phosphatidylserine 0.1 part.
3. the preparation method of the medicine comprising Stigma Maydis and Phosphatidylserine as described in claim 1-2 is arbitrary, it is characterised in that specifically comprise the following steps that
(1) each raw material is weighed according to weight portion；
(2) drying by Stigma Maydis natural drying or in the environment of Stigma Maydis is positioned over 60-70 DEG C, adds the water of 3-15 times, temperature controls at 80-110 DEG C, refluxes and extracts 0.5-4h continuously；
(3) the extracting solution temperature that step (2) obtains being reduced to 70-90 ° of C, carry out evacuation being compressed to relative density is 1.0-1.1；
(4) carry out after initial filter fine straining again, obtain Stigma Maydis extract；
(5) Stigma Maydis extract adds Phosphatidylserine, after stirring, obtain pharmaceutical preparation.
The preparation method of the medicine comprising Stigma Maydis and Phosphatidylserine the most according to claim 3, it is characterised in that described pharmaceutical preparation is beverage, tea, tablet, granule or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610214198.2A CN105816705A (en) | 2016-04-07 | 2016-04-07 | Corn stigma and phosphatidylserine-containing drug and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610214198.2A CN105816705A (en) | 2016-04-07 | 2016-04-07 | Corn stigma and phosphatidylserine-containing drug and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816705A true CN105816705A (en) | 2016-08-03 |
Family
ID=56525782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610214198.2A Pending CN105816705A (en) | 2016-04-07 | 2016-04-07 | Corn stigma and phosphatidylserine-containing drug and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816705A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1625406A (en) * | 2001-08-09 | 2005-06-08 | 底古萨食品配料有限公司 | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| CN1638779A (en) * | 2001-10-05 | 2005-07-13 | 拜奥格辉特·拜奥嘉德有限公司及两合公司 | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| CN102908336A (en) * | 2011-08-05 | 2013-02-06 | 深圳市华正实业有限公司 | Stable preparation of phosphatidylserine and preparation method, application as well as application product of stable preparation |
| CN104146254A (en) * | 2014-08-14 | 2014-11-19 | 胡安然 | Full-nutrition formulated food for hypertension |
| CN104256642A (en) * | 2014-10-10 | 2015-01-07 | 胡安然 | Fully nutrient formula food for lowering high blood pressure, high blood sugar and high blood lipid and strengthening yang |
| CN104768558A (en) * | 2012-10-22 | 2015-07-08 | 维勒加研发有限公司 | Lactagogue composition based on phosphatidylserine |
| CN104855983A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-complete nutritional formula food for coronary heart disease |
-
2016
- 2016-04-07 CN CN201610214198.2A patent/CN105816705A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1625406A (en) * | 2001-08-09 | 2005-06-08 | 底古萨食品配料有限公司 | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| CN1638779A (en) * | 2001-10-05 | 2005-07-13 | 拜奥格辉特·拜奥嘉德有限公司及两合公司 | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| CN102908336A (en) * | 2011-08-05 | 2013-02-06 | 深圳市华正实业有限公司 | Stable preparation of phosphatidylserine and preparation method, application as well as application product of stable preparation |
| CN104768558A (en) * | 2012-10-22 | 2015-07-08 | 维勒加研发有限公司 | Lactagogue composition based on phosphatidylserine |
| CN104146254A (en) * | 2014-08-14 | 2014-11-19 | 胡安然 | Full-nutrition formulated food for hypertension |
| CN104256642A (en) * | 2014-10-10 | 2015-01-07 | 胡安然 | Fully nutrient formula food for lowering high blood pressure, high blood sugar and high blood lipid and strengthening yang |
| CN104855983A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-complete nutritional formula food for coronary heart disease |
Non-Patent Citations (2)
| Title |
|---|
| 周鸿立 等: "玉米须降血糖活性部位的筛选研究", 《上海中医药杂志》 * |
| 董长颖 等: "玉米须水提物的利尿作用及抗菌活性研究", 《黑龙江畜牧兽医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101637255B (en) | Hypoglycemic nutrition powder | |
| CN102907604B (en) | Health-care product having effects of reducing blood sugar and pressure, losing weight, relaxing bowels, maintaining beauty and resisting fatigue and production process thereof | |
| CN103891963B (en) | Hypoglycemic health protection tea of a kind of reducing blood pressure and blood fat and preparation method thereof | |
| CN104719535A (en) | Maca black tea composition capable of improving sub-health status of women and preparation method of maca black tea composition | |
| CN103099089A (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN102630790B (en) | Tartary buckwheat tea prepared by Ginkgo biloba leaf and preparation process thereof | |
| CN101926945B (en) | Natural plant health care product capable of calming heart, refreshing mind, tonifying brain and improving intellectual development and preparation method thereof | |
| CN102048224B (en) | Red jujube health-care beverage capable of removing chloasma, beautifying features and improving skin, and production technology thereof | |
| CN112315995A (en) | Composition containing acer truncatum seed oil and preparation method thereof | |
| CN109700011A (en) | A kind of health food and preparation method thereof improving sleep | |
| CN104095231A (en) | Health-care product containing mair conditioning unita, dendrobium and American ginseng and preparation method thereof | |
| CN116076710A (en) | Rose herbal ferment with anti-aging and whitening functions and preparation method and application thereof | |
| CN104126803A (en) | Health-care product for supplementing nutrition of heart and brain, soothing heart and benefiting brain | |
| CN101491338A (en) | Nutrient food capable of improving sleep and preparation method thereof | |
| CN103610077A (en) | Sea cucumber capsule | |
| CN101185706A (en) | Hippophae rhamnoides nutrition mixture with delaying senility function and preparation technique thereof | |
| CN105249440A (en) | Donkey-hide gelatin cake | |
| CN105726612A (en) | Drug containing herba rhodiolae and phosphatidylserine and preparation method of drug | |
| CN109619189A (en) | A kind of black fruit Sorbus alnifloria eye protecting milk tablet of sea-buckthorn and preparation method thereof | |
| CN103005439B (en) | Bitter gourd compound lipid-lowering oral solution and preparation method thereof | |
| CN102119939A (en) | Angiosperm bee pollen water extract for treating fatty liver and preparation method and application thereof | |
| CN101810679A (en) | Polyunsaturated fatty acid soft capsule and preparation method thereof | |
| CN104783174A (en) | Preparation method of pure natural nutritional, immune and health solid beverage | |
| CN110024941A (en) | A kind of composition and its application with blood-enrich function | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |
|
| RJ01 | Rejection of invention patent application after publication |